Testing IASO208 for relapsed or hard-to-treat B-cell cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment called IASO208 for people with certain types of B-cell lymphoma that have come back or not responded to standard treatments. It aims to see if the drug can help shrink tumors and control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between the ages of 18 and 75.
- You have been diagnosed with a specific type of B-cell lymphoma, such as diffuse large B-cell lymphoma or mantle cell lymphoma, and it has come back or not gotten better with standard treatment.
- Your tumor still has a protein called CD20 on its surface (doctors will check this).
- You have at least one tumor that can be measured on a scan (at least 1.5 cm in size for lymph nodes or 1 cm for other areas).
- You are able to walk and care for yourself (ECOG score 0-2).
- Your heart, liver, kidneys, and blood counts are working well enough based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IASO-782 for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) who haven't gotten better with standard treatments. The goal is to see if the drug can help control the immune system and improve blood counts.
This study tests a new treatment called OriV508 for people with blood cancers (multiple myeloma or aggressive B-cell lymphoma) that have not responded to at least two previous therapies. It aims to see if the treatment is safe and helps shrink or control the cancer.
This early-stage trial tests IASO207, a new injection designed to treat B-cell lymphomas (blood cancers) that have come back or stopped responding to standard treatments. The drug targets a protein called CD19 found on cancer cells.
This trial tests a new treatment called IASO206 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if IASO206 can help control the cancer.
This trial tests a new type of cell therapy (IASO206) for patients whose autoimmune hemolytic anemia (a condition where the body attacks its own red blood cells) has not responded to standard treatments. The therapy is designed to target and control the immune cells causing the problem.
This early-stage trial tests IASO207, a new cell therapy designed to help people with severe lupus that hasn't improved with standard medications. The therapy works by modifying immune cells to reduce lupus activity.
Hear when a new Relapsed/Refractory B-cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.